BENDHEIM JACK 4
4 · PHIBRO ANIMAL HEALTH CORP · Filed Mar 26, 2026
Research Summary
AI-generated summary of this filing
Phibro (PAHC) Director Jack Bendheim Sells 21,120 Shares
What Happened
Jack Bendheim, a director and 10% owner of Phibro Animal Health Corp. (PAHC), sold a total of 21,120 shares in open-market transactions between March 24–26, 2026. The individual lots reported: 6,523; 517; 1,572; 4,916; 552; 6,760; and 280 shares, producing aggregate proceeds of approximately $1,166,105. Prices on the reported lots were weighted averages across multiple executions, with transaction-level weighted prices reported from about $52.88 up to $57.17 and price ranges in the filing spanning roughly $52.44 to $57.24. These were sales (S) — typically routine disposition transactions rather than purchases.
Key Details
- Dates: March 24, 25 and 26, 2026. Filing date: March 26, 2026 (timely).
- Shares sold: 21,120 total; aggregate proceeds ≈ $1,166,105.
- Reported prices: weighted-average per lot (examples: $52.88, $53.59, $55.28, $56.00, $56.86, $56.79, $57.17); overall reported ranges ~$52.44–$57.24 (see footnotes).
- Beneficial ownership after the transactions: not specified in the provided summary of the filing.
- Notable footnotes: sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC (Dec 11, 2025). Some reported securities are directly held by BFI (over which Mr. Bendheim exercises voting and dispositive power) while others are directly held by Jack Bendheim; footnotes note weighted-average pricing and provide price ranges for multiple executions.
- Transaction type/code: S = Sale. Filing appears timely (no late filing flag).
Context
These transactions were executed under a pre-established Rule 10b5-1 plan (a common mechanism that allows insiders to sell shares according to a predetermined schedule), and some shares involved entities (BFI) where Mr. Bendheim has control. Sales under a 10b5-1 plan are generally viewed as planned dispositions and do not necessarily signal a change in the insider’s view of the company. As always, retail investors should consider insider trades alongside broader fundamentals and other disclosures.
Insider Transaction Report
- Sale
Class A Common Stock
[F1][F2][F3]2026-03-24$52.88/sh−6,523$344,918→ 66,797 total(indirect: See) - Sale
Class A Common Stock
[F1][F4][F3]2026-03-24$53.59/sh−517$27,705→ 66,280 total(indirect: See) - Sale
Class A Common Stock
[F1][F5][F3]2026-03-25$55.28/sh−1,572$86,904→ 64,708 total(indirect: See) - Sale
Class A Common Stock
[F1][F6][F3]2026-03-25$56.00/sh−4,916$275,316→ 59,792 total(indirect: See) - Sale
Class A Common Stock
[F1][F7][F3]2026-03-25$56.86/sh−552$31,386→ 59,240 total(indirect: See) - Sale
Class A Common Stock
[F1][F8][F3]2026-03-26$56.79/sh−6,760$383,868→ 52,480 total(indirect: See) - Sale
Class A Common Stock
[F1][F9][F3]2026-03-26$57.17/sh−280$16,008→ 52,200 total(indirect: See)
- 16,840
Class A Common Stock
[F10]
Footnotes (10)
- [F1]The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.
- [F10]The reported securities are directly held by Jack Bendheim.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.44 to $53.435. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 4 through 9.
- [F3]The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
- [F4]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.53 to $53.70.
- [F5]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.69 to $55.65.
- [F6]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.76 to $56.745.
- [F7]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.76 to $56.91.
- [F8]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.12 to $57.06.
- [F9]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.14 to $57.24.